Recombinant Human PIM1, N-His

Description of Recombinant Human PIM1, N-His

Introduction

Recombinant Human PIM1, N-His is a protein that plays a critical role in cellular signaling and regulation. It belongs to the PIM family of serine/threonine kinases and is involved in various cellular processes such as cell proliferation, survival, and differentiation. This protein has gained significant attention as a potential drug target due to its involvement in various diseases, including cancer and inflammatory disorders.

Structure of Recombinant Human PIM1, N-His

Recombinant Human PIM1, N-His is a 33 kDa protein that consists of 313 amino acids. It has a highly conserved kinase domain with a typical N-terminal catalytic domain and a C-terminal regulatory domain. The catalytic domain contains the ATP binding site, while the regulatory domain contains the phosphorylation sites and the PIM1-specific motifs. The protein also has a unique N-terminal extension, N-His tag, which is added during the recombinant production process for purification and detection purposes.

Activity of this protein

Recombinant Human PIM1, N-His is a serine/threonine kinase that phosphorylates target proteins to regulate their activity. It has been found to phosphorylate a variety of substrates, including transcription factors, cell cycle regulators, and other kinases. This protein is highly active in cancer cells, where it promotes cell proliferation and survival by phosphorylating key targets involved in these processes. It has also been implicated in the regulation of apoptosis, cell cycle progression, and DNA damage response.

Application of Recombinant Human PIM1, N-His

As a potential drug target, Recombinant Human PIM1, N-His has been extensively studied in various diseases, particularly cancer. Its overexpression has been observed in several cancer types, including prostate, breast, and leukemia, making it a promising target for cancer therapy. Inhibition of PIM1 activity has been shown to reduce tumor growth and sensitize cancer cells to chemotherapy and radiation therapy.

Apart from cancer, Recombinant Human PIM1, N-His has also been implicated in other diseases, including inflammatory disorders such as rheumatoid arthritis and psoriasis. In these diseases, PIM1 has been found to regulate the production of pro-inflammatory cytokines, making it a potential target for anti-inflammatory therapies.

The recombinant production of PIM1, N-His has also allowed for the development of specific inhibitors targeting this protein. These inhibitors have shown promising results in pre-clinical studies and are currently being evaluated in clinical trials for the treatment of cancer and other diseases.

Conclusion

In summary, Recombinant Human PIM1, N-His is a 33 kDa protein that belongs to the PIM family of serine/threonine kinases. It plays a critical role in cellular signaling and is involved in various cellular processes such as cell proliferation, survival, and differentiation. Its overexpression has been observed in cancer and inflammatory disorders, making it a potential drug target. The recombinant production of this protein has allowed for the development of specific inhibitors, which are currently being evaluated in clinical trials. Further research on Recombinant Human PIM1, N-His and its role in disease pathogenesis could lead to the development of novel and effective therapies for various diseases.